Cole and Jaenisch dig into AI poisoning in pharma manufacturing, how it hides in plain sight, and who should be accountable for catching it.
|Articles|March 2, 2019
- Pharmaceutical Technology-03-02-2019
- Volume 43
- Issue 3
Reactor Flask Heating System
The DrySyn UNO Base by Asynt offers a way to conduct safe experiments in academic teaching and research labs.
The DrySyn UNO Base by Asynt offers a way to conduct safe experiments in academic teaching and research labs. The versatile entry-level reactor flask heating system has a heat resistant handle that enables safe heating and clamping of a single flask or vial using a DrySyn Reaction Vial insert.
The base itself has a flat bottom with removable/repositionable feet that makes it suitable for use on any standard magnetic hotplate stirrer. The base is constructed of solid anodized aluminum, which enhances the heating system’s performance without the need for messy and potentially hazardous oil baths, according to the company.
Articles in this issue
over 7 years ago
Tablet Press Refurbishment: Why and How?over 7 years ago
Embracing the Digital Factory for Bio/Pharma Manufacturingover 7 years ago
Caught in a Conundrumover 7 years ago
Strategic Screening for Solubility Solutionsover 7 years ago
Monoplant: Advantages of a Dedicated Facilityover 7 years ago
Handle with Careover 7 years ago
Rising to the Challenge of Biologic Drug Formulationover 7 years ago
Can the Price Ever be Right?over 7 years ago
Europe Pushes for Global Easing of Generics Approvalsover 7 years ago
Key Considerations in Stability TestingRelated to this article
Mahmood Majeed, ZS, explains why measurable AI outcomes in pharma supply chain and manufacturing jumped from 29% to 53%, and how GMP limits and GxP validation shape adoption.
BMS-Tempus, Roche-Zymeworks, and LGM-Sannova deals show what AI data, trispecifics, and nitrosamine testing mean for CMC, QA, and development teams.
Univar Solutions scientists developed a lidocaine cream built on starch, sorbitol, coconut oil, and beeswax that matched a commercial benchmark on viscosity, assay, and hydration.
Nate Edwards of Arya Consulting moderates a discussion with Elisabeth Gardiner of Tevard Biosciences and Donny Xu of the RTW Institute about the regulatory and manufacturing hurdles facing rare disease drug developers.
FDA grants ravulizumab accelerated approval in IgA nephropathy after a 43.4% proteinuria cut, signaling new IV biologic demand for drug manufacturers.
Jane Zhang of ETCH Sourcing explains why geopolitics, transparency, and partnership now weigh as heavily as cost and quality when companies choose suppliers, in this episode of Ask the Expert, moderated by Susan J. Schniepp of Nelson Labs.
FDA approves GSK's bepirovirsen for chronic hepatitis B after a 19% functional cure rate, raising oligonucleotide scale-up stakes for manufacturers.
Trending on Pharmaceutical Technology
1
AAPS PharmSci 360 2026: E&L Standards Harmonization
2
Nitrosamine Problems and Industry Solutions: PharmTech Explained
3
OpenAI Bets on Accelerating Drug Development Timelines With Orchestra Bio
4
AAPS PharmSci 360 2026: System Suitability Standards in E&L Testing
5